LDS/Medical Tests/Cytochrome P450 3A7 (CYP3A7) Genotyping

Cytochrome P450 3A7 (CYP3A7) Genotyping

The cytochrome P450 (CYP450) enzymes are heme-thionate monooxygenases that metabolize the majority of drugs as well as organic compounds in our body, and are involved in synthesis of cholesterol, steroids and certain lipids. Most of CYP450 enzyme family members are expressed in the liver. The expression level of different CYP enzymes varies. The expression levels and/or activities of CYPs of each individual are affected by factors like genetic polymorphism, disease condition, and inducing or inhibitory chemicals. Evidence shows that genetic polymorphisms of different CYP genes, which largely depend on ethnicity, are clinically important regarding drug dosing, drug efficacy, and adverse drug reactions (ADRs). The CYP3A subfamily is among the most important category of CYP450 enzymes, which metabolizes about ~30% of total clinically used drugs. It is the most prevalent P450 enzyme in the liver.

The CYP3A subfamily comprises four CYP genes 3A4, 3A5, 3A7, and 3A43. They are present on chromosome 7q21.1. The percentages of CYPs 3A4, 3A5, 3A7, and 3A43 proteins of adult liver CYP3A protein amount are estimated 85.4%, 5.4%, 3.4%, and 5.8%, respectively. The CYP3A7 gene is the predominant gene/enzyme in the fetal liver and gradually is replaced by CYP3A4 as a person matures into adulthood. Two CYP3A7 variants have been found to cause the high expression phenotype of the gene; star1C and star 2, which causes about a 10 fold higher CYP3A7 protein level in the liver. Recently, a null CYP3A7 *3 has been found in the Korean population, but not in Caucasians and African Americans. Because the sequences among different CYP3A isozymes are similar, they have highly similar substrate selectivity. Due to the largely overlapped substrates with other CYP3A enzymes, the clinical significance of these CYP3A7 polymorphisms have not been well understood.

  • Help determine therapeutic strategy for drugs metabolized by CYP3A7 proteins
Increased eznyme activity is seen in \*1C, \*2 variants  Decreased in enzyme activity is seen in \*3 variants  CYP3A7 substrate: Tretinoin, Fluticasone Propionate, Cilostazol, Buprenorphine, Midazolam, Retinoic Acid, Dehydroepiandrosterone, Retin-A, Estrone, Testosterone CYP3A7 inhibitor: Midazolam, nelfinavir, ritonavir, Azamulin, troleandomycin

CYP3A7 \*1/\*1 (Normal metabolizer)

Allele Specific Primer Extension (ARMS) by Real-time Polymerase chain reaction (PCR), Next generation sequencing (NGS), Conventional Sequencing.

Whole blood collected in lavender top tube (EDTA) or any anticoagulant collection devices, buccal swab, saliva. 

Stability

  • Ambient: 5 days
  • Refrigerated: 7 days
Genetic test of other CYP3A genes, CYP3A4 and CYP3A5.
3-7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login